Sage Journals: Discover world-class research

Abstract

Background

The impact of cancer on outcomes was not assessed in major trials of systemic thrombolysis in acute ischemic stroke.

Aims

To evaluate the association between comorbid cancer and hospital outcomes among patients receiving systemic thrombolysis for the treatment of acute ischemic stroke.

Methods

The 2013 and 2014 United States National Inpatient Sample was used to identify adult patients hospitalized for acute ischemic stroke who received systemic thrombolysis. Identified admissions were stratified into two cohorts based on the presence or absence of comorbid cancer. Multivariable logistic regression was performed to determine the association between comorbid cancer and the odds of in-hospital mortality and intracerebral hemorrhage after adjustment for age ≥75 years and comorbid atrial fibrillation.

Results

A total of 13,993 acute ischemic stroke admissions were treated with systemic thrombolysis. Of these, 3.0% (n = 416) had comorbid cancer. The overall incidence of in-hospital mortality was 7.0% and intracerebral hemorrhage occurred in 7.6% of patients. Upon multivariable adjustment, comorbid cancer was not associated with an increased odds of in-hospital mortality (odds ratio = 1.24; 95% confidence interval = 0.88–1.76). However, the adjusted odds of intracerebral hemorrhage were higher among those with comorbid cancer (odds ratio = 1.60; 95% confidence interval = 1.17–2.17).

Conclusions

In this retrospective study of admissions for acute ischemic stroke receiving thrombolysis, comorbid cancer was not associated with a higher odds of in-hospital mortality but was associated with an increased odds of intracerebral hemorrhage. Factors driving this observed association should be explored in data sets containing clinical variables.

Keywords

Stroke neoplasms thrombolytic therapy mortality intracerebral hemorrhage tissue plasminogen activator thrombolysis

Get full access to this article

View all access options for this article.

References

Grisold

Oberndorfer

Struhal

. Stroke and cancer: a review. Acta Neurol Scand 2009; 119: 1–16.

Jauch

Saver

Adams

et al.

Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870–947.

Powers

Derdeyn

Biller

et al.

American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46: 3020–3035.

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581–1587.

Lee

Chung

Ahn

et al.

Hypercoagulability and mortality of patients with stroke and active cancer: the OASIS-CANCER study. J Stroke 2017; 19: 77–87.

HCUP Databases: Healthcare Cost and Utilization Project (HCUP), 2013–2014. Rockville, MD: Agency for Healthcare Research and Quality, https://www.hcup-us.ahrq.gov/databases.jsp (accessed 29 September, 2017).

Weimar

König

Kraywinkel

Ziegler

Diener

. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke 2004; 35: 158–162.

Andersen

Olsen

. Predictors of early and late case-fatality in a nationwide Danish study of 26,818 patients with first-ever ischemic stroke. Stroke 2011; 42: 2806–2812.

Frankel

Morgenstern

Kwiatkowski

et al.

Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology 2000; 55: 952–959.

10.

König

Ziegler

Bluhmki

et al.

Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke 2008; 39: 1821–1826.

11.

Murthy

Karanth

Shah

et al.

Thrombolysis for acute ischemic stroke in patients with cancer: a population study. Stroke 2013; 44: 3573–3576.

12.

Graham

. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003; 34: 2847–2850.

13.

Velander

DeAngelis

Navi

. Intracranial hemorrhage in patients with cancer. Curr Atheroscler Rep 2012; 14: 281–373.

14.

Chen

C-Y

Tai

C-H

Cheng

et al.

Intracranial hemorrhage in adult patients with hematological malignancies. BMC Med 2012; 10: 97–105.

15.

Hauser

Lechner

. Solid tumors and factor VIII antibodies. Thromb Haemost 1999; 82: 1005–1007.

16.

Masrur

Abdullah

Smith

et al.

Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy. J Stroke Cerebrovasc Dis 2011; 20: 124–130.

17.

Nam

Kim

et al.

Intravenous thrombolysis in acute ischemic stroke with active cancer. Biomed Res Int 2017; 2017: 4635829.

18.

Arboix

. Cerebrovascular disease in the cancer patient. Rev Neurol 2000; 31: 1250–1252.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.23 MB

Association between comorbid cancer and outcomes among admissions for acute ischemic stroke receiving systemic thrombolysis

Abstract

Background

Aims

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material